Brain scans studying amyloid and sugar use in people at risk of Alzheimer's disease
Uses brain PET scans to study early Alzheimer's changes in cognitively healthy adults.
Plain-language title generated from the registry record
Registry title: Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men and women already in the ALFA project who have normal thinking and memory. They will have brain PET scans.
- Age
- 45 to 75 years
- Sex
- Men and women
- Disease stage
- No memory or thinking problems: MMSE of 26 or more, Semantic Fluency (animals) of 12 or more, and a CDR score of 0.
- Earlier treatment
- Cannot have joined a study of an investigational drug within 30 days before screening, or have had a radiopharmaceutical within 10 radioactive half-lives before study drug administration.
Main reasons for not taking part
- Memory or thinking problems
- Serious psychiatric disorder such as major depression, schizophrenia or bipolar disorder
- Vision or hearing problems
- History of encephalitis, stroke or seizures (childhood fever seizures do not count)
- Cannot have an MRI scan, for example because of metal implants
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 75 years old?
Source: NCT02685969, who can take part
Where in Spain
- Barcelonabeta Brain Research CenterBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
- Trial code
- NCT02685969
- Record updated
- 31 May 2025
- Original description
Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.Read full original descriptionShow less
Characterization of Cerebral Amyloid Deposition With 18F-Flutemetamol PET and of Glucose Metabolism With 18F-FDG PET in Individuals Enrolled in the ALFA Project.
Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.
Cross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project.
Study without therapeutic interest for the research participants (440 participants of the ALFA project who have been selected for being cognitively healthy and in their vast majority are direct descendants of patients diagnosed with Alzheimer's Disease).
Each study candidate will be selected from the ALFA project (STUDY 45-65 FPM/2012) according to their clinical characteristics, their compliance to selection criteria and their desire to participate in this study.
After signing this study's specific informed consent form, the neuropsychological screening and the brain MRI acquisition will be performed. Once all inclusion criteria are checked, the PET scans with 18F-Flutemetamol and 18F-FDG will be performed
Inclusion: To sign the study informed consent form approved by the corresponding authorities; Men and women enrolled in the ALFA project (STUDY 45-65 FPM/2012); Participants with a cerebral MRI (magnetic resonance imaging) not suggestive of radiological incidental findings constituting an exclusion criterion; Cognition within psychometrically normal ranges: MMSE (Mini Mental State Examination ≥26 and Semantic Fluency (animals) ≥12; Score of 0 in the CDR scale (Clinical Dementia Rating); Good knowledge of the language and being literate; Female participants should be post-menopausal or present a negative pregnancy test at the moment of PET acquisition.
Exclusion: Any contraindication to MRI acquisition, (i.e., metal implants) or phobia to performing the scan as determined by the onsite physician; Previous participation in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study; Present cognitive impairment; Presence of clinically relevant psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia or bipolar disorder; Individuals with visual and/or hearing impairment; History of encephalitis, ictus or seizures excluding feverish convulsions during childhood; Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor (metastasis/brain cancer) as verified by magnetic resonance imaging (MRI).